A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus genome. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.

Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine.

The present invention relates to a method for prevention and/or reduction of aggregation of viral components.

A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

A coxsackievirus B4 strain and application thereof are disclosed. The strain is named KM140-G01 and is preserved in China Center for Type Culture Collection (CCTCC) on Jun. 18, 2023, and the preservation number is CCTCC NO: V202356, the preservation address is Wuhan University, China. The strain is a humanized coxsackievirus B4 wild type single purified strain, and has strong virus replication capacity, good genetic stability and immunogenicity; the strain can be applied to the development of human coxsackievirus B4 vaccine production strains, and is suitable for the development of attenuated coxsackievirus B4 vaccine and inactivated coxsackievirus B4 vaccine; the method can also be used for establishing an infection model on Vero cells and suckling mice, and is used for CVB4 infection and pathogenic mechanism research, CVB4 vaccine evaluation and antiviral drug screening.

Virus particle multimers and methods of making and using such virus particle multimer are described. Virus particle multimers are constructed by preparing a plurality of asymmetrically functionalized virus particles bearing one or more functional groups and contacting the asymmetrically functionalized virus particles with a first linker molecule that reacts with the functional groups to form a virus particle multimer that includes a plurality of asymmetrically functionalized virus particles connected by the linker molecule. The asymmetrically functionalized virus particles are typically prepared by attaching the virus particles to a support surface to allow asymmetrical functionalization to be introduced.